New data shows Cabotegravir CAB-LA PrEP is Both Acceptable and Feasible in Practice
A recent study highlights the promising potential of Cabotegravir (CAB-LA) as a long-acting pre-exposure prophylaxis (PrEP) for HIV prevention. Published in the Infectious Disease Special